Abstract:
PROBLEM TO BE SOLVED: To provide a self-adhesive composition, and a percutaneous absorption-type preparation containing a rubber-based self-adhesive, having an excellent control ability of bleeding, and controlling an increase in crystal deposition of a medicament with time. SOLUTION: The self-adhesive composition used for the percutaneous absorption-type preparation includes: the medicament; a medicament solubilizer for improving the solubility of the medicament; the rubber-based self-adhesive; polyvinylpyrrolidone; and a higher fatty acid. The polyvinylpyrrolidone is contained in an amount effective for inhibiting volatilization of the medicament solubilizer. The higher fatty acid preferably contains isostearic acid. The medicament solubilizer preferably contains N-methyl-2-pyrrolidone. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for external application and an adhesive skin patch capable of improving releasability, transdermal absorbability and stability of loxoprofen and a salt thereof and capable of reducing aggravation of irritation to skin.SOLUTION: An adhesive skin patch includes a support and an adhesive layer laminated on the support. The adhesive layer includes a styrene-isoprene-styrene copolymer, a tackifier, a plasticizer, sodium loxoprofen, oxyacid and N-methyl-2-pyrrolidone. Preferably, the adhesive layer includes no crotamiton.
Abstract:
Disclosed are a pharmaceutical composition for external application, an a dhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingre dient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch comprising a support and an adhesive layer laminated on the support, wherein the adhesive layer c ontains a pharmaceutical composition for external application. The pharmaceu tical composition for external application comprises a pharmacologically act ive ingredient, an auxiliary component and a pyrrolidone compound, wherein o ne of the pharmacologically active ingredient and the auxiliary component ha s a carboxylate group in the molecule and the other has a hydroxy group in t he molecule. Preferably, the adhesive layer further comprises a hydrogenated oil.
Abstract:
Preparación absorbible por vía transdérmica, que tiene un soporte y una capa de adhesivo que se coloca sobre el soporte y que contiene un agente adhesivo y un componente farmacéutico, comprendiendo el agente adhesivo una mezcla de resina que comprende 100 partes en masa de un copolímero acrílico (A) descrito a continuación y de 0,1 a 30 partes en masa de un copolímero acrílico (B) descrito a continuación o de 0,05 a 2 partes en masa de un compuesto de poliamina, y comprendiendo además la capa de adhesivo un ácido orgánico, en la que dicho copolímero acrílico (A) es un copolímero acrílico que comprende un éster alquílico de ácido (met)acrílico como componente de monómero principal, y comprende del 3 al 45% en masa de diacetona-acrilamida como componente de monómero esencial, pero no comprende un grupo carboxilo libre y en la que dicho copolímero acrílico (B) es un copolímero acrílico que comprende un éster alquílico de ácido (met)acrílico como componente de monómero principal, y comprende un grupo amino primario y/o un grupo carboxihidrazida en las cadenas laterales, pero no comprende un grupo carboxilo libre.